Gsk5764227

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

16 Countries

Phase III

Phase I/II

Phase III: 1 Phase I/II: 3

Sponsors using this IMP

Glaxosmithkline Research & Development Limited 4

All trials

4 total

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Pending

2025-523997-18-00 Phase I/II 1 country Glaxosmithkline Research & Development Limited
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Phase III 13 countries Glaxosmithkline Research & Development Limited
A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting

2025-522274-37-00 Phase I/II 1 country Glaxosmithkline Research & Development Limited
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Phase I/II 10 countries Glaxosmithkline Research & Development Limited

Showing 1–4 of 4 trials

← All drugs A–Z